MTRC is starting to provide services of developing value dossiers for medical device and IVD companies

24

Sep 2019

Every innovative technology has the challenge to communicate the value to different stakeholders. Why this health care problem is important (mortality, morbidity, impact on quality of life, cost-of-illness)? What are the current treatment options and what are their limitations? What is the size of the population with high unmet need? What is the proposed novel solution? Is it safe and effective? What are the economic consequences to the hospital and health care system? What are the organizational requirements for the introduction of a novel method?

Historically, these questions were answered by separate publications in peer-reviewed journals and marketing materials. However, they are typically not comprehensive enough, lack of important information and too unstructured to support discussion with clinicians, reimbursement authorities and payers.

The modern answer to the challenge of summarizing and presenting the value of the technology is the value dossier. Value dossier is the document of a certain structure that summarizes in a comprehensive and unbiased way all value-related messages for medical technology. The document is also used as a source for information for any reimbursement-related activities: from supporting local business case to application to national HTA.

There are two formats of the value dossier: early dossier - a relatively short (15-20 pages) documents, based on systematic but limited search with the focus on the key messages and data; core value dossier is more comprehensive document (typically about 60-100 pages plus supplements) that includes more argumentation and more value messages.

MTRC can provide support with development of both early and core value dossiers. Typically, dossier is developed either from a global or European perspective.

Historically, these questions were answered by separate publications in peer-reviewed journals and marketing materials. However, they are typically not comprehensive enough, lack of important information and too unstructured to support discussion with clinicians, reimbursement authorities and payers.

The modern answer to the challenge of summarizing and presenting the value of the technology is the value dossier. Value dossier is the document of a certain structure that summarizes in a comprehensive and unbiased way all value-related messages for medical technology. The document is also used as a source for information for any reimbursement-related activities: from supporting a local business case to the application to national HTA.

There are two formats of the value dossier: early dossier - a relatively short (15-20 pages) documents, based on systematic but limited search with the focus on the key messages and data; core value dossier is more comprehensive document (typically about 60-100 pages plus supplements) that includes more argumentation and more value messages.

MTRC can provide support with the development of both early and core value dossiers. Typically, dossier is developed either from a global or European perspective.

Learn more here: https://services.mtrconsult.com/valuedossier

The latest related news

22

Nov 2021

In August, MTRC launched two subscription services with a focus on all published, initiated or ongoing HTA and reimbursement reports and decisions for medical devices, procedures and IVD tests. HTA Alerts is a global service and covers 56 organizations from 24 countries. Reimbursement Alerts is focused on 14 key European countries. All alerts are tailed to the technologies of interest for each client. You can request a free-of-charge 2-month sample of reporting for both services

Read more

23

Sep 2021

In September 2021, MTRC received a certificate of conformity of the internal processes with the ISO 9001:2015 (quality management systems) standard. The certificate was issued by the United Kingdom Accreditation Service, UKAS. This confirms the commitment of the MTRC team to the provision of high-quality reimbursement services in Europe.

Read more

03

Aug 2021

A syndicated report (135 pages) reviews details of innovation funding and coverage with evidence development schemes in Europe, including Austria, Belgium, England, France, Germany, the Netherlands, and Switzerland. For each scheme, information about objective, inclusion criteria, applicant, stakeholders involved, clinical and economic evidence requirements, and statistics (including at least 2019-2020 data; but for most schemes – statistics for multiple years) is included.

Read more

12

Jul 2021

MTRC released an update of the syndicated report on reimbursement decisions for IVD tests in 5 EU countries (Belgium, France, Germany, the Netherlands, and Switzerland). The updated report covers 3-year period of 2018-2020. Broader coverage gives a better understanding of the activity of the reimbursement organizations.

Read more

17

May 2021

In August, MTRC launched two subscription services with a focus on all published, initiated or ongoing HTA and reimbursement reports and decisions for medical devices, procedures and IVD tests. HTA Alerts is a global service and covers 56 organizations from 24 countries. Reimbursement Alerts is focused on 14 key European countries. All alerts are tailed to the technologies of interest for each client. You can request a free-of-charge 2-month sample of reporting for both services

Read more